BOCOM INTL: Maintains Hutchmed (China) 'Buy' rating, Target Price raised to 44 HKD.

BOCOM INTL released a research report stating that it maintains a "Buy" rating for Hutchmed (China) (00013), believing that the transaction conditions are reasonable and favorable for the company's long-term development. The earnings forecast has been adjusted, and the DCF Target Price has been raised to 44 Hong Kong dollars. The company has made continuous key progress in the development of pipelines in the mid to late stage, with relevant catalysts to look forward to in 2025, including: 1) Based on the success of the SAVANNAH study, partner AstraZeneca will soon submit the first overseas NDA for Savolitinib to the FDA (2/3 LMET abnormal treatment-resistant NSCLC); 2) China Phase III SACHI study.

Sina Hong Kong stocks09:39

J&J Lung Cancer Treatment Extends Lives Versus AstraZeneca Drug | NYSE:JNJ

Proactive Investors02:33

Unusual Options Activity: BP, TPR and Others Attract Market Bets, BP V/OI Ratio Reaches 156.3

EST Jan 7th Afternoon Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options

Futu News02:30

J&J Rybrevant/Lazcluze Combo Bests AstraZeneca's Tagrisso in NSCLC

Seeking AlphaJan 7 23:27

Johnson & Johnson Reports 'Statistically Significant' Data From Trial of Rybrevant, Lazcluze Combination to Treat Lung Cancer

MT NewswiresJan 7 21:55

Express News | Refile-Buzz-Obesity Drugs, M&a Among Key Pharma Drivers for 2025, Berenberg Says

BreakingsJan 7 21:22